Purple Biotech (PPBT) News Today $3.11 -0.10 (-3.12%) (As of 11/1/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Purple Biotech Advances with CAPTN-3 Cancer PlatformOctober 25, 2024 | markets.businessinsider.comPurple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer TherapeuticsOctober 25, 2024 | globenewswire.comPurple Biotech Unveils CAPTN-3 Cancer TherapyOctober 11, 2024 | finance.yahoo.comPurple Biotech to Present Data for its Tri-Specific Antibody Platform—CAPTN-3—at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer TherapeuticsOctober 10, 2024 | globenewswire.comPurple Biotech (NASDAQ:PPBT) Stock Quotes, Forecast and News SummaryOctober 4, 2024 | benzinga.comQ3 2024 EPS Estimates for Purple Biotech Ltd Reduced by Analyst (NASDAQ:PPBT)Purple Biotech Ltd (NASDAQ:PPBT - Free Report) - Analysts at HC Wainwright cut their Q3 2024 EPS estimates for Purple Biotech in a research report issued on Thursday, September 19th. HC Wainwright analyst E. Bodnar now forecasts that the company will earn ($1.20) per share for the quarter, down fSeptember 23, 2024 | marketbeat.comPurple Biotech (NASDAQ:PPBT) PT Raised to $33.00 at HC WainwrightHC Wainwright upped their price target on Purple Biotech from $8.00 to $33.00 and gave the stock a "buy" rating in a research note on Friday.September 20, 2024 | marketbeat.comBuy Rating Justified by Promising CM24 Phase 2 Study for Pancreatic Cancer SurvivalSeptember 19, 2024 | markets.businessinsider.comPurple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24September 18, 2024 | globenewswire.comPurple Biotech Ltd (1YI1.MU)September 17, 2024 | uk.finance.yahoo.com1YI1.SG,0P0001D6KB,0 (1YI1.SG)September 17, 2024 | au.finance.yahoo.comPurple Biotech Ltd (1YI1.DU)September 17, 2024 | sg.finance.yahoo.comPurple Biotech to Present Data for its Lead Oncology Drug CM24 at the AACR Special Conference on Advances in Pancreatic Cancer ResearchSeptember 10, 2024 | markets.businessinsider.comPurple Biotech to Participate at H.C. Wainwright 26th Annual Global Investment ConferenceAugust 30, 2024 | globenewswire.comPPBT Purple Biotech LtdAugust 24, 2024 | seekingalpha.comPurple Biotech Ltd.: Purple Biotech Reports Second Quarter 2024 Financial Results and Business HighlightsAugust 16, 2024 | finanznachrichten.dePurple Holds its Own on Quarterly NumbersAugust 16, 2024 | msn.comPurple Biotech Reports Second Quarter 2024 Financial Results and Business HighlightsAugust 16, 2024 | globenewswire.comPurple Biotech Ltd (PPBT.TA)August 8, 2024 | finance.yahoo.comPurple Biotech Ltd.: Purple Biotech Receives Extension to Regain Compliance with the Nasdaq's Minimum Bid Price RuleJuly 25, 2024 | finanznachrichten.dePurple Biotech Receives Extension to Regain Compliance with the Nasdaq’s Minimum Bid Price RuleJuly 25, 2024 | finance.yahoo.comPurple Biotech Receives Extension to Regain Compliance with the Nasdaq's Minimum Bid Price RuleJuly 25, 2024 | globenewswire.comPurple Biotech to Host Virtual KOL Event to Discuss Positive Interim Results from Phase 2 Pancreatic Cancer Study with CM24 on July 11, 2024July 10, 2024 | globenewswire.comPurple Biotech Announces Closing of Exercise of Warrants for $2 Million Gross ProceedsJuly 2, 2024 | globenewswire.comPurple Biotech Announces Exercise of Warrants for $2 Million Gross ProceedsJuly 1, 2024 | globenewswire.comPurple Biotech Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival BenefitJune 27, 2024 | globenewswire.comPurple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic CancerJune 1, 2024 | globenewswire.comBuy Rating Justified by Purple Biotech’s Promising Clinical Data and Market PotentialMay 21, 2024 | markets.businessinsider.comPurple Biotech Ltd.: Purple Biotech Reports First Quarter 2024 Financial ResultsMay 21, 2024 | finanznachrichten.dePPBT Stock Earnings: Purple Biotech Beats EPS for Q1 2024May 21, 2024 | msn.comPurple Biotech Reports First Quarter 2024 Financial ResultsMay 21, 2024 | globenewswire.comBuy Rating Affirmed on Purple Biotech’s CM24 Favorable Interim Phase 2 Results in PDAC TreatmentApril 26, 2024 | markets.businessinsider.comPurple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual MeetingApril 25, 2024 | globenewswire.comPurple Biotech Ltd (PPBT)April 17, 2024 | investing.comPurple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024March 28, 2024 | finance.yahoo.comPurple Biotech Ltd.: Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform TechnologyMarch 14, 2024 | finanznachrichten.dePurple Biotech Reports Preclinical Proof of Concept for its Tribody Platform TechnologyMarch 14, 2024 | globenewswire.comPromising Pipeline Prospects for Purple Biotech: Buy Rating Affirmed Amidst Anticipated Clinical AdvancementsMarch 6, 2024 | markets.businessinsider.comPPBT Stock Earnings: Purple Biotech Meets EPS for Q4 2023March 5, 2024 | investorplace.comPurple Biotech Ltd.: Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial ResultsMarch 5, 2024 | finanznachrichten.dePurple Biotech Reports Fourth Quarter and Full-Year 2023 Financial ResultsMarch 5, 2024 | globenewswire.comPurple Biotech ADR (PPBT) Earnings Dates & ReportsMarch 3, 2024 | investing.comBuy Rating Justified by Promising Phase 1 Results of Purple Biotech’s NT219 in SCCHN TreatmentFebruary 27, 2024 | markets.businessinsider.comPurple Biotech Ltd ADRFebruary 27, 2024 | morningstar.comPurple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024February 27, 2024 | globenewswire.comPurple Biotech Ltd. ADRFebruary 22, 2024 | wsj.comPurple Biotech Ltd ADR PPBTFebruary 15, 2024 | morningstar.comPurple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 TrialFebruary 13, 2024 | finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: Purple Biotech (PPBT) and Sanofi (OtherSNYNF)February 1, 2024 | markets.businessinsider.comPurple Biotech stock climbs 9% on Phase 2 study updateFebruary 1, 2024 | msn.com Get Purple Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for PPBT and its competitors with MarketBeat's FREE daily newsletter. Email Address 625,000% Gain (Ad)Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz. >> Dive into the Workshop Here PPBT Media Mentions By Week PPBT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PPBT News Sentiment▼0.000.42▲Average Medical News Sentiment PPBT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PPBT Articles This Week▼01▲PPBT Articles Average Week Get Purple Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for PPBT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies SCYNEXIS News Today Synlogic News Today Zevra Therapeutics News Today Amylyx Pharmaceuticals News Today YS Biopharma News Today Jasper Therapeutics News Today Lexeo Therapeutics News Today biote News Today Aurora Cannabis News Today Rezolute News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PPBT) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Purple Biotech Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Purple Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
